Introduction
Survivin, a member of the inhibitor of apoptosis (IAP) gene family (Deveraux and Reed, 1999) , is emerging as a promising therapeutic target in cancer (Altieri, 2003b) . Intense study of Survivin over the past few years has revealed several prominent features that distinguish it from other IAPs (i.e. XIAP, cIAP-1, cIAP-2, Livin). First, although most IAPs are expressed ubiquitously, Survivin is generally not expressed in normal tissues but broadly expressed in cancer (Ambrosini et al., 1997) . It was in fact among the most cancer-specific genes identified by transcriptomal analysis (Velculescu et al., 1999) , and Survivin expression has been correlated with tumor aggression and poor prognosis for many cancers including melanoma (Takeuchi et al., 2005) , breast cancer (van 't Veer et al., 2002) and neuroblastoma (Azuhata et al., 2001) . Second, in contrast to other IAPs that primarily confer apoptotic protection through binding and inactivation of caspases (Deveraux and Reed, 1999) , Survivin additionally appears to regulate mitochondrial apoptosis upstream of caspase activation and may also protect cells against caspase-independent apoptosis (Shankar et al., 2001; Beltrami et al., 2004; Liu et al., 2004) . Third, Survivin is a multifunctional protein regulating cell viability at the level of mitotic (Li et al., 1998; Vong et al., 2005) and stress response (Fortugno et al., 2003) checkpoints, as well as apoptosis. Taken together, these characteristics of Survivinnamely its cancer-specific expression and central importance in maintaining cellular viability -make it a particularly attractive therapeutic target in cancer.
A variety of strategies have successfully been employed for Survivin targeting, and numerous studies have demonstrated that inhibition of Survivin in malignant (but not untransformed) cells results in spontaneous activation of caspase and mitochondrial apoptotic pathways (Altieri, 2003a) . Approaches in which Survivin was targeted at the RNA level include antisense (Grossman et al., 1999) , RNA interference (Ling and Li, 2004) and ribozyme (Pennati et al., 2002) . Point mutations in the conserved baculovirus IAP repeat (BIR) domain of Survivin (such as Survivin-C84A) prevent requisite dimerization of the Survivin molecule, and result in dominant-negative mutants that interfere with endogenous wild-type Survivin in cells (Muchmore et al., 2000) . An additional dominant-negative mutant in which Thr 34 is mutated to Ala (Survivin-T34A) blocks a conserved phosphorylation site for cdc2-cyclin B1 and prevents Survivin binding to activated caspase-9 (O'Connor et al., 2000) . When introduced into malignant Survivin-expressing cells, mutants such as Survivin-T34A result in apoptosis and profound mitotic defects including aberrant mitotic figures and multinucleated cells . Recent discovery of the interaction between Survivin and Hsp90 by Altieri and co-workers (Fortugno et al., 2003) led to the design of Survivin peptides (termed 'shepherdin') corresponding to the Hsp90-binding site that induced apoptosis in tumor cells (Plescia et al., 2005) . We initially demonstrated in melanoma cell lines stably transfected with an inducible Survivin-T34A construct that Survivin targeting prevented xenograft tumor formation and reduced growth of established tumors (Grossman et al., 2001) . Subsequent preclinical studies by others demonstrated that intratumoral injection of plasmids encoding Survivin antisense and Survivin-C84A (Kanwar et al., 2001) , or adenovirus expressing Survivin-T34A (Mesri et al., 2001) , reduced tumor growth.
Most relevant to systemic apoptosis-based cancer therapy, however, is the development of models in which proapoptotic agents can be delivered to tumor cells at distant sites and (in the case of many cancers such as melanoma) traverse the blood-brain barrier. Dowdy and co-workers (Becker-Hapak et al., 2001) developed the use of an HIV-derived TAT peptide sequence for efficient protein transduction into cells, and showed that TAT peptide fusion proteins rapidly enter mouse tissues, including the brain, following intraperitoneal (i.p.) injection (Schwarze et al., 1999) . Following this approach, we constructed a recombinant TAT-Survivin-T34A fusion protein and found that this cell-permeable Survivin antagonist induces apoptosis in melanoma cells and that i.p. injection slows growth of established subcutaneous tumors.
Results and discussion

Generation of TAT-Survivin proteins and cellular entry
We had previously demonstrated that an inducible phosphorylation-deficient dominant-negative Survivin mutant (Survivin-T34A) functioned as an effective Survivin antagonist, inducing melanoma cell apoptosis and inhibiting tumor growth in vivo (Grossman et al., 2001) . To generate a proapoptotic Survivin targeting molecule for cellular delivery, a Survivin-T34A mutant was expressed as a recombinant fusion protein containing the TAT protein transduction domain (Figure 1a) . A similar construct containing the wild-type Survivin sequence (TAT-Surv-WT) was also generated, and these TAT-Surv proteins were expressed in Escherichia coli. Following sequential purification by affinity chromatography and ion-exchange chromatography, both TATSurv proteins were visualized as single bands migrating at B28 kDa on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 1b) .
To assess cellular entry, YUSAC2 melanoma cells (Grossman et al., 1999) were incubated with fluorescein isothiocyanate (FITC)-conjugated TAT-Surv proteins and then analyzed by flow cytometry. As shown in Figure 2a , dose-dependent entry of TAT-Surv proteins was seen at concentrations of 30-100 nM, compared to that of bovine serum albumin (BSA)-FITC, which served as a nonspecific control. Nonspecific staining with BSA-FITC was only seen at higher (300 nM) concentrations (Figure 2a ). Cellular entry of TATSurv-FITC proteins, but not BSA-FITC, was visualized in both YUSAC2 and WM793 melanoma cells at 30 nM concentrations (Figure 2b ). Transfection studies have demonstrated Survivin localization to multiple cellular compartments including nucleus and cytosol (Caldas et al., 2005) , and we observed similar localization patterns for the TAT-Surv-FITC proteins (Figure 2b ). To determine the stability of the fusion proteins in culture, cells were examined over a 48-h period by Western blotting. Both TAT-Surv proteins could easily be detected at 12 and 24 h following addition, but the proteins were largely degraded by 48 h (Figure 2c ).
Induction of apoptosis
Incubation with TAT-Surv-T34A, but not TAT-Surv-WT, induced detachment of WM793 ( Figure 3a ) and YUSAC2 cells (not shown). Both cell lines incubated with TAT-Surv-T34A underwent apoptosis as reflected by accumulation of cells with sub-diploid DNA content ( Figure 3b ). By contrast, treatment with TAT-Surv-WT did not induce significant apoptosis (Figure 3b ). Consistent with the capacity of TAT-Surv-T34A to induce DNA fragmentation, we also observed significant caspase-3 activation in both cell lines treated with TATSurv-T34A compared to TAT-Surv-WT ( Figure 3c ). We had previously observed translocation of mitochondrial apoptosis-inducing factor (AIF) to be an early event in Survivin-targeted melanoma cells (Liu et al., 2004) . Similarly, YUSAC2 cells treated with TAT-Surv-T34A exhibited AIF translocation from mitochondria to cytosol in contrast to untreated cells or cells treated with TAT-Surv-WT (Figure 3d) . Thus, the TAT-Surv-T34A recombinant protein displayed proapoptotic activities (on both cell lines at low mM concentrations) comparable to those seen previously (Grossman et al., 2001; Liu et al., 2004) upon plasmid-based expression of Survivin-T34A.
Tumor penetration and apoptotic effects of TAT-Survivin proteins in vivo Next, we assessed the in vivo activity of the TAT-Surv proteins using YUSAC2 cells in a xenograft model, as we had previously characterized the capacity of these cells to form subcutaneous tumors in immunodeficient mice (Grossman et al., 2001) . To confirm that the TATSurv proteins could be delivered to tumors at a distant site, FITC-conjugated TAT-Surv proteins were injected (10 mg/kg) i.p. into mice with established tumors, and 1 h later, tumors were harvested and examined by fluorescence microscopy. As shown in Figure 4a , tumors from animals injected with either TAT-Surv-WT-FITC or TAT-Surv-T34A-FITC, but not BSA-FITC, demonstrated significant protein (FITC) accumulation. Tumors from separate animals were then examined 24 h after i.p. injection for rates of tumor cell apoptosis and mitosis by TdT-mediated dUTP nick end labeling (TUNEL) and bromodeoxyuridine (BrdU) staining, respectively. There was a higher apoptotic index (21.7 vs 15%, P ¼ 0.007) and lower mitotic index (5.9 vs 7.6%, P ¼ 0.14) in tumors from animals treated with TAT-Surv-T34A compared to TAT-Surv-WT ( Figure  4b and c). We also examined these tumors microscopically for the presence of aberrant nuclei and mitotic figures, features characteristic of Survivin inhibition , and found significantly (P ¼ 0.0001) increased numbers of aberrant nuclei (Figure 4d ) in tumors from animals injected with TAT-Surv-T34A compared to TAT-Surv-WT (Figure 4e) .
Finally, we examined the effect of repeated dosing of these TAT proteins on tumor growth. Animals bearing subcutaneous tumors were injected i.p. with TAT-Surv-WT, TAT-Surv-T34A or saline buffer every 3 days, and tumor growth was monitored over a 3-week period. As shown in Figure 5a , there was a 40-50% reduction (Po0.05) in tumor growth in animals treated with TATSurv-T34A compared to those receiving TAT-Surv-WT or saline buffer. Consistent with these measurements, final tumor weight was significantly decreased (P ¼ 0.02, 0.01) at the experimental end point in TAT-Surv-T34A-treated animals (Figure 5b ). The TAT-Surv-T34A protein appeared to be non-toxic, not affecting the activity, feeding or body weight of these animals. Although treatment with TAT-Surv-WT appeared to slightly enhance tumor growth compared to the saline control (Figure 5a ), the two average tumor growth curves and final tumor weights were not significantly different. We performed a second experiment under similar conditions, and a significant (Po0.05) inhibitory effect of TAT-Surv-T34A vs saline buffer on tumor growth was again observed (not shown).
Survivin-targeted therapies
In summary, we generated a recombinant fusion protein incorporating a TAT peptide transduction domain and a Survivin dominant-negative mutant. This cellpermeable Survivin antagonist efficiently entered cells and induced apoptosis characterized by DNA fragmentation, caspase-3 activation and mitochondrial AIF translocation, comparable to that seen in previous studies (Grossman et al., 2001; Liu et al., 2004) with Survivin-T34A and other Survivin antagonists. Tumors are most vulnerable to Survivin targeting during mitosis, leading to characteristic mitotic defects and ultimately apoptosis . The TAT-Surv proteins could be delivered to subcutaneous tumors by i.p. injection, and delivery of TAT-Surv-T34A resulted in increased tumor cell apoptosis and aberrant nuclei, and was associated with a 40-50% reduction in the growth of established tumors.
These studies demonstrate the feasibility of systemic tumor treatment using a cell-permeable Survivin antagonist. The recombinant TAT-Survivin-T34A protein is clearly superior to previously characterized Survivin antagonists that were delivered by lipid-based transfection (Grossman et al., 1999) or adenovirus (Mesri et al., 2001) , stably integrated into the cellular genome (Grossman et al., 2001) or involved direct intratumoral injection (Kanwar et al., 2001; Mesri et al., 2001) . Efficient cellular entry resulting from incorporation of the TAT peptide transduction domain resulted not only in proapoptotic activities at low mM concentrations, but more importantly, permitted systemic treatment to a distant tumor. This approach will likely be suitable for other tumor types, as cell-permeable Survivin shepherdin peptides have been recently described with similar activities on tumor cells derived from prostate and breast cancer (Plescia et al., 2005) . Despite their capacity to induce significant cell death in cultured cells, however, none of these agents has been shown to cause tumor regression. Although concentrations of Survivin antagonist delivered to tumor tissue may not approach those achieved in tissue culture, tumor persistence is more likely owing to survival signals supplied by interactions with adjacent cells and extracellular matrix that account for increased apoptosis resistance in vivo. Nevertheless, the ability of these cell-permeable Survivin antagonists to slow tumor growth may ultimately be sufficient to have clinical impact, but it will be important to evaluate their activity further in combination with other therapeutic modalities in metastatic and survival tumor models.
Materials and methods
TAT fusion proteins
A SalI fragment containing cDNA encoding the 140 amino acids and stop codon of mouse Survivin was cloned into the XhoI site of pCMV-HA (Clontech, Palo Alto, CA, USA), yielding pHA-WT. A mutation was introduced at residue 34 (T34A) (Grossman et al., 2001) by DpnI-based mutagenesis as described in the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), with complimentary primers 5 0 -CCTCCGCCATTCGCTCTGGGG cGCAGGCGCAGTCC-3 0 and 5 0 -GGACTGCGCCTGCgCCC CAGAGCGAATGGCGGAGG-3 0 (mutation in lower case), yielding pHA-T34A. This region in the Survivin BIR domain is highly conserved between human (Ambrosini et al., 1997) and mouse . The desired mutation and absence of additional mutations was confirmed by DNA sequencing. The wild-type Survivin and Survivin-T34A sequences were amplified by PCR from pHA-WT and pHA-T34A, respectively, using primers 5 0 -GGCTCCATGGGAGCTCCGGCGCTGCC-3 0 and 5 0 -CCGGCTCGAGTTAGGCAGCCAGCTGCTCAATTG AC-3 0 , incorporating internal NcoI and XhoI restriction sites (underlined). The amplified fragments were digested with NcoI and XhoI, and cloned into the NcoI/XhoI sites of pTAT-HA (Nagahara et al., 1998) (kindly provided by Steven Dowdy, University of California San Diego School of Medicine) downstream of the TAT (YGRKKRRQRRR) peptide transduction domain. Correct orientation, preservation of reading frame and absence of additional mutations were confirmed by DNA sequencing.
The TAT-Surv fusion proteins were expressed in E. coli (BL-21, Novagen, Madison, WI, USA) and purified by ionexchange chromatography as described (Becker-Hapak et al., 2001 ) with some modifications. Briefly, transformed bacteria were grown in LB medium containing ampicillin, and 1 mM IPTG (Invitrogen, Carlsbad, CA, USA) was added for the final 4-5 h of culture for induction of maximal protein expression. After centrifugation, pellets were lysed in 8 M urea and sonicated. Sonicates were loaded onto Ni-NTA agarose beads (Qiagen, Valencia, CA, USA), and after washing with 8 M urea containing 0.5 M sodium chloride, the His-tagged proteins were eluted in 8 M urea containing 0.25-0.5 M imidazole, 0.1 M sodium chloride and 10 mM Tris, pH 6.5, and stored at room temperature. Protein production and purification were monitored on Coomassie-stained 10-15% SDS-PAGE gels. Final purification and removal of urea was accomplished using a Pharmacia Mono-Q column equilibrated with 4 M urea, 50 mM sodium chloride and 20 mM Hepes, pH 8.0 at 41C. Protein fractions were diluted 1:1 with 20 mM Hepes, pH 8.0, then 1:10 with 4 M urea, 50 mM sodium chloride and 20 mM Hepes, pH 8.0, before loading. After washing with 20 mM Hepes, pH 8.0, TAT fusion proteins were eluted with 1 M sodium chloride containing 20 mM Hepes, pH 8.0, and quantitated using the BCA kit (Pierce, Rockford, IL, USA). Approximately 1 mg protein was ultimately recovered per 100 ml of bacterial culture. Proteins were stored in 1 M sodium chloride containing 20 mM Hepes, pH 8.0, and 10% glycerol at À801C, and used within 6 weeks.
Melanoma cells
Melanoma cell lines YUSAC2 (Grossman et al., 1999) and WM793 (kindly provided by Meenhard Herlyn, Wistar Institute, Philadelphia, PA, USA) (Satyamoorthy et al., 2003) were maintained in medium containing antibiotics in a humidified incubator as described.
Cellular transduction
Purified TAT-Surv proteins and BSA (Pierce, Rockford, IL, USA) were each conjugated with a 2 M excess of FITC (Pierce) in 0.1 M sodium bicarbonate, pH 9, for 1 h under foil at room temperature. After dialysing against phosphate-buffered saline (PBS), glycerol was added (10% final concentration) and FITC-labeled proteins were stored at À801C. FITC-labeled proteins were added to adherent sub-confluent (30-50%) cells, and after incubation for 1 h at 371C, cells were recovered by trypsinization and analysed by flow cytometry.
For fluorescence microscopy, cells were plated onto coverslips before addition of FITC-labeled proteins. Coverslips were washed with PBS, briefly incubated in 4% paraformaldehyde in PBS containing 0.1% Triton X-100, washed in water, then inverted and adhered to glass slides using a mounting solution containing 4,6-diamidino-2-phenylindole (DAPI) (Grossman et al., 1999) . Cells were visualized using an Olympus IX70 fluorescence microscope, and images were obtained with an Olympus Microfire camera and overlaid using Pictureframe software (Optronics, Goleta, CA, USA). Images were cropped, merged into panels, and colors for each panel were simultaneously optimized in Photoshop.
Protein stability experiments were performed in six-well plates. Following incubation, cells were lysed in buffer containing 2% SDS, and protease and phosphatase inhibitor cocktails (Sigma Chemical Co, St Louis, MO, USA) were added before Western blotting (Grossman et al., 1999) using antibodies against Survivin (Grossman et al., 1999) , hemagglutinin (HA) (Sigma) and Actin (Sigma) as indicated.
Apoptosis detection
Cells were plated at 30% confluency in six-well plates. The TAT-Surv proteins were added to the medium, and cells were returned to the incubator. Late-stage apoptosis was assessed by total cellular DNA content using propidium iodide and flow cytometry as described previously (Liu et al., 2004) . Caspase-3 activity was measured in sonicated cell lysates using the fluorogenic substrate Ac-DEVD-AMC as described previously (Liu et al., 2004) . To detect AIF translocation, treated cells were fractionated into cytosolic and mitochondrial components, and lysates were analysed by Western blotting as described previously (Liu et al., 2004) .
Mouse tumor studies Melanoma xenografts were established by subcutaneous injection of 2.5 Â 10 6 YUSAC2 cells into the flank of CB17SCRF immunodeficient mice (Taconic Farms, Germantown, NY, USA) as described previously (Grossman et al., 2001) For studies on tumor growth, mice bearing tumor xenografts reaching approximately 50 mm 3 were injected i.p. every 3 days with saline buffer or 200 mg TAT-Surv proteins. Tumors were measured by caliper every 3 days over an 18-day period. Tumors were harvested 24 h after the final injection and weighed.
Statistics
Selected data were subjected to unpaired t-tests with Welch's correction using Prism (Graphpad Software, San Diego, CA, USA). P-values o0.05 were considered statistically significant.
